Clinical Trials on Primary Peritoneal Transitional Cell Carcinoma

Total 17058 results

National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Shaheen Alanee
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

Endoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial Cells

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Clear... and other conditions

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma

Transitional Cell Carcinoma of Urinary Tract

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
Cliniques universitaires Saint-Luc- Université...
Novartis

Terminated

Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy (BEZ235)

Carcinoma Transitional Cell

Belgium, Luxembourg
Associació per a la Recerca Oncologica, Spain

Unknown

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Urothelium Transitional Cell Carcinoma

Spain, Netherlands
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Transitional Cell Carcinoma | Metastatic Urothelial Carcinoma | Unresectable Transitional Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Bladder Cancer | Metastatic Transitional Cell Carcinoma

United States
Pierre Fabre Medicament

Completed

JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (JASINT1)

Bladder Transitional Cell Carcinoma Stage IV

France
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium

Metastatic Transitional Cell Carcinoma of the Urothelium

United States
Institute of Cancer Research, United Kingdom
Cancer Research UK

Unknown

A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) (POUT)

Transitional Cell Carcinoma of Ureter

United Kingdom
Lipac Oncology LLC
TesoRx Pharma, LLC

Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Urologic Neoplasms | Urogenital Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Non-Muscle Invasive Bladder Cancer | Urinary Bladder | Bladder Cancer Cell Transitional

United States
Trans Tasman Radiation Oncology Group
National Health and Medical Research Council, Australia

Completed

Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.

Transitional Cell Carcinoma of Urinary Bladder

Australia, New Zealand
Anchiano Therapeutics Israel Ltd.

Completed

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Transitional Cell Carcinoma of Bladder

Israel
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Malignant Ovarian Brenner Tumor and other conditions

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Transitional Cell Carcinoma

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Transitional Cell Carcinoma

United States
Princess Al-Johara Al-Ibrahim Cancer Research Center

Completed

A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine (ALA)

Transitional Cell Carcinoma of the Bladder

Saudi Arabia
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
Noah Hahn, M.D.
Pfizer; Hoosier Cancer Research Network

Terminated

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Transitional Cell Carcinoma of the Bladder

United States, United Kingdom
Hoosier Cancer Research Network
Bristol-Myers Squibb

Completed

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Transitional Cell Carcinoma of the Bladder

United States
University of Michigan

Completed

Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer (SPARC)

Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
Yale University

Withdrawn

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Transitional Cell Carcinoma

United States
Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
Lahey Clinic

Withdrawn

Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer

Transitional Cell Carcinoma

United States
Cliniques universitaires Saint-Luc- Université...

Completed

A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy

Transitional Cell Carcinoma

Belgium
Far Eastern Memorial Hospital

Unknown

The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma

Carcinoma, Transitional Cell

Taiwan
Guru P. Sonpavde
QED Therapeutics, Inc.

Withdrawn

Phase I BLASST-3 Trial ((BLASST)-3)

Bladder Cancer | Bladder Transitional Cell Carcinoma | Fibroblast Growth Factor Receptor
Zetiq Technologies

Unknown

Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology

Bladder Cancer Transitional Cell Carcinoma

Israel
National Cancer Institute (NCI)

Terminated

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Transitional Cell Carcinoma of the Bladder | Localized Transitional Cell Cancer of the...

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Transitional Cell Carcinoma of Bladder

Italy
University of Washington
National Cancer Institute (NCI)

Terminated

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Ovarian... and other conditions

United States
Sunnybrook Health Sciences Centre
Celgene Corporation

Completed

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Transitional Cell Carcinoma

Canada
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; AstraZe... and other collaborators

Completed

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Transitional Cell Carcinoma | Bladder Cancer

United States
Erasmus Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

Biomarkers | Transitional Cell Carcinoma of the Bladder

Netherlands
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
Kaohsiung Medical University

Completed

Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma

Carcinoma, Transitional Cell (RENI)
Oncolytics Biotech

Withdrawn

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Muscle-invasive Transitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center
Pfizer

Terminated

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Recurrent Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
SCRI Development Innovations, LLC
Celgene

Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma

United States

Clinical Trials on Primary Peritoneal Transitional Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations